Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study Various Arab news Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study AETOS Wire 21 June، 2023 in Patients with Relapsed/Refractory B-cell Malignancies CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on...Read More
